Fortress Biotech, Inc.

FBIO

US34960Q3074

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-09 pm EDT			5-day change	1st Jan Change
3.370 ^USD	+0.90%		+2.12%	-7.92%

Feb. 23	Fortress Biotech Subsidiary Agrees to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million	MT
Jan. 13	Fortress Biotech shares hit near two-week low, last down 6.6%	RE

Fortress Biotech, Cyprium Say FDA Approved Zycubo for Pediatric Patients of Menkes Disease; Shares Rise Pre-Bell

Published on 01/13/2026 at 08:26 am EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Fortress Biotech, Inc.

Feb. 23	Fortress Biotech Subsidiary Agrees to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million	MT
Jan. 13	Fortress Biotech shares hit near two-week low, last down 6.6%	RE
Jan. 13	Fortress Biotech and Cyprium Therapeutics Announce U.S. Fda Approval of Zycubo	CI
Jan. 13	Fortress Biotech, Cyprium Say FDA Approved Zycubo for Pediatric Patients of Menkes Disease; Shares Rise Pre-Bell	MT
Jan. 13	US FDA approves Fortress Bio and Zydus' treatment for a rare pediatric disease	RE
Jan. 13	Fortress Biotech and Cyprium Therapeutics announce U.S. FDA approval of Zycubo® (copper histidinate), the first and only approved treatment for Menkes disease in the United States	RE
Dec. 15	Fortress Biotech, Inc. Enters into First Amendment to Credit Agreement	CI
Dec. 15	Fortress Biotech, Inc. and Cyprium Therapeutics, Inc. Announce FDA Acceptance of CUTX-101 NDA Resubmission	CI
Dec. 15	Fortress Biotech Rises After FDA Accepts Application for Menkes Treatment	DJ
Dec. 15	Fortress Biotech, Cyprium get FDA acceptance for CUTX-101 NDA resubmission	RE
Nov. 17	Fortress Biotech says on Nov 14, Sentynl notified Cyprium that Sentynl had resubmitted the NDA for Cutx-101 to the FDA	RE
Nov. 14	Fortress Biotech Q3 revenue up 20.5%, Checkpoint sale nets $28 mln	RE
Nov. 14	Fortress Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 12	Fortress Biotech, Inc., Q3 2025 Earnings Call, Nov 12, 2025
25-10-21	Fortress Biotech and subsidiary Urica Therapeutics announce first patients dosed in Crystalys Therapeutics' global phase 3 trials of Dotinurad for the treatment of gout	RE

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has seven marketed prescription pharmaceutical products and over 25 programs in development at the Company, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Such product candidates span six market areas, including oncology, rare diseases and gene therapy. Its dermatology products include Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Exelderm and Luxamend. Its late stage product candidates include Cosibelimab (anti-PD-L1 antibody), DFD-29 (modified release oral minocycline for the treatment of rosacea), CUTX-101 (copper histidinate injection for Menkes disease), IV Tramadol, Olafertinib (also known as CK-101, EGFR inhibitor for EGFR mutation-positive NSCLC), CAEL-101 (monoclonal antibody for AL amyloidosis) and Triplex (cytomegalovirus (CMV) vaccine).

Employees

101

Sector

Pharmaceuticals

More about the company